Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.

Alcoholism, clinical and experimental research - 1 Oct 2020

Anton Raymond F, Voronin Konstantin E, Book Sarah W, Latham Patricia K, Randall Patrick K, Glen Willam Bailey, Hoffman Michaela, Schacht Joseph P

Abstract excerpt

BACKGROUND: While the opiate antagonist, naltrexone, is approved for treating alcohol use disorder (AUD), not everyone who receives the medication benefits from it. This study evaluated whether the OPRM1 SNP rs1799971 interacts with the dopamine transporter gene DAT1/SLC6A3 VNTR rs28363170 or the catechol-O-methyltransferase (COMT) gene SNP rs4680 in predicting naltrexone response. METHODS: Individuals who met...

Read the complete abstract on PubMed

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcoholism
Share to Catechol O-Methyltransferase
Share to Dopamine Plasma Membrane Transport Proteins
Share to Genotype
Share to Naltrexone
Share to Polymorphism, Single Nucleotide
Share to Receptors, Opioid, mu
Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 32772383
DOI: 10.1111/acer.14431
PMCID: PMC8080431

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.PMID 32772383Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.Semantic proximity Read ↗

Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.Semantic proximity Read ↗

Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.Semantic proximity Read ↗

Opioid pharmacogenetics of alcohol addiction.Semantic proximity Read ↗

Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol.Semantic proximity Read ↗

OPRM1 rs1799971 Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation.Semantic proximity Read ↗

Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.Semantic proximity Read ↗

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone.Semantic proximity Read ↗

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Semantic proximity Read ↗

COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.